Epigral Reports Strong Q2 FY27 With PAT Surging 26% YoY to ₹64 Crore
Epigral Ltd · Press Release · 02 Nov 2026, 7:29 pm
Epigral Reports Strong Q2 FY27 With PAT Surging 26% YoY to ₹64 Crore Epigral reported a 26% YoY rise in Q2 FY27 PAT to ₹64 Cr, while revenue increased 28% YoY to ₹752 Cr, driven by improved realisations and 6% sales volume growth. Derivatives and Specialty contribution rose to 57% of revenue versus 50% in Q2 FY26. EBITDA grew to ₹136 Cr, with margins at 18% due to elevated raw material costs. For H1 FY27, revenue reached ₹1,461 Cr and PAT hit ₹164 Cr. Expansions in CPVC and ECH are slated for commissioning within a quarter.
Original exchange filing (PDF)
More announcements from Epigral Ltd
- One-on-One Meeting through Video Conferencing (V.C.) with Kotak Mahindra Asset Management (Singapore) Pte Ltd on Thursday, 19th November, 2026. · 18 Nov 2026
- One-on-One Meeting through Video Conferencing (V.C.) with Kitara Capital on Friday, 20th November, 2026. · 18 Nov 2026
- Epigral Limited submits Transcript of conference call held on Monday, 2nd November, 2026 discussing Q2 FY2027 Results. · 08 Nov 2026
- Audio Recording of Conference Call discussing Q2 FY27 Results held on Monday, 2nd November, 2026 at 5.00 P.M. · 03 Nov 2026
- INVESTOR PRESENTATION - Q2 FY27. · 02 Nov 2026
- UNAUDITED FINANCIAL RESULTS - 30.09.2026 · 02 Nov 2026
- Epigral Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 02 Nov 2026
- Outcome of Board Meeting held on Monday, 2nd November, 2026 and submission of Un-Audited Financial Results (Standalone & Consolidated) for the Second Quarter and Half Year ended 30th, September, 2026 · 02 Nov 2026
